Skip to main content

Rydym wedi cadw rhai ffeiliau o'r enw cwcis ar eich dyfais. Y cwcis hyn yw:

  • Hanfodol ar gyfer y safle i weithio
  • Helpu i wella ein gwefan drwy gasglu ac adrodd gwybodaeth am sut rydych chi'n ei defnyddio

Hoffem hefyd arbed rhai cwcis i helpu i deilwra cyfathrebu.

BETA
Rydych yn edrych ar fersiwn wedi'i ddiweddaru o'r gwasanaeth hwn - bydd eich adborth yn ein helpu i'w wella.

Hysbysiad o Gontract

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B

  • Cyhoeddwyd gyntaf: 08 Ionawr 2022
  • Wedi'i addasu ddiwethaf: 08 Ionawr 2022

Nid yw'r prynwr yn defnyddio'r wefan hon i weinyddu'r hysbysiad.

I gofnodi eich diddordeb neu gael gwybodaeth neu ddogfennau ychwanegol, darllenwch y cyfarwyddiadau yn Nhestun Llawn yr Hysbysiad. (NODER: Nid oes angen ymateb i Hysbysiadau Dyfarnu Contractau a Hysbysiadau Gwybodaeth Ymlaen Llaw fel arfer)

Cynnwys

Crynodeb

OCID:
Cyhoeddwyd gan:
The NHS Commissioning Board (operating under the name of NHS England)
ID Awudurdod:
AA73994
Dyddiad cyhoeddi:
08 Ionawr 2022
Dyddiad Cau:
14 Chwefror 2022
Math o hysbysiad:
Hysbysiad o Gontract
Mae ganddo ddogfennau:
Nac Ydi
Wedi SPD:
Nac Ydi
Mae ganddo gynllun lleihau carbon:
AMH

Crynodeb

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Testun llawn y rhybydd

Hysbysiad contract

Adran I: Endid contractio

I.1) Enw a chyfeiriad

The NHS Commissioning Board (operating under the name of NHS England)

2nd Floor, Rutland House

Runcorn

WA7 2ES

UK

Person cyswllt: Philip Grieve

E-bost: philip.grieve@nhs.net

NUTS: UK

Cyfeiriad(au) rhyngrwyd

Prif gyfeiriad: https://www.england.nhs.uk/

Cyfeiriad proffil y prynwr: https://www.england.nhs.uk/

I.2) Caffael ar y cyd

Caiff y contract ei ddyfarnu gan gorff prynu canolog

I.3) Cyfathrebu

Mae'r dogfennau caffael ar gael ar gyfer mynediad uniongyrchol anghyfyngedig a llawn, yn rhad ac am ddim ar:

http://health.atamis.co.uk


Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod


Rhaid anfon tendrau neu geisiadau i gymryd rhan yn electronig at:

http://health.atamis.co.uk


Rhaid anfon tendrau neu geisiadau i gymryd rhan i'r cyfeiriad uchod:


Mae cyfathrebu electronig yn gofyn am ddefnyddio offer a dyfeisiau nad ydynt ar gael yn gyffredinol. Mae mynediad uniongyrchol anghyfgyfyngiedig a llawn i'r offer a dyfeisiau hyn yn bosibl, yn rhad ac am ddim, yn:

http://health.atamis.co.uk


I.4) Y math o awdurdod contractio

Gweinyddiaeth neu unrhyw awdurdod cenedlaethol neu ffederal arall, gan gynnwys eu his-adrannau rhanbarthol neu leol

I.5) Prif weithgaredd

Iechyd

Adran II: Gwrthrych

II.1) Cwmpas y caffaeliad

II.1.1) Teitl

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B

Cyfeirnod: CM/PHS/19/5576

II.1.2) Prif god CPV

33141530

 

II.1.3) Y math o gontract

Cyflenwadau

II.1.4) Disgrifiad byr

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.1.5) Cyfanswm gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 500 000 000.00 GBP

II.1.6) Gwybodaeth am lotiau

Mae’r contract hwn wedi’i rannu’n lotiau: Ydy

Gellir cyflwyno tendrau ar gyfer pob lot

II.2) Disgrifiad

Rhif y Lot 1

II.2.1) Teitl

Lot 1 - eftrenonacog alfa (rFIX EHL)

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 2

II.2.1) Teitl

Lot 2 - albutrepenonacog alfa (rFIX EHL)

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 3

II.2.1) Teitl

Lot 3 - nonacog beta pegol (rFIX EHL)

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 4

II.2.1) Teitl

Lot 4 - rFIX - Standard Half Life

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 5

II.2.1) Teitl

Lot 5 - Recombinant Factor VII

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 6

II.2.1) Teitl

Lot 6 - Porcine Factor VIII - susoctocog alfa

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 7

II.2.1) Teitl

Lot 7 - Factor VIII Inhibitor Bypassing Fraction

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 8

II.2.1) Teitl

Lot 8 - Factor IX - High Purity Factor IX

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 9

II.2.1) Teitl

Lot 9 - Factor X

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 10

II.2.1) Teitl

Lot 10 - Factor XIII - Plasma Derived

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 11

II.2.1) Teitl

Lot 11 - Factor XIII - Recombinant

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 12

II.2.1) Teitl

Lot 12 - Factor VIII/ von willebrands factor

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 13

II.2.1) Teitl

Lot 13 - Von willebrands factor - Plasma Derived

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 14

II.2.1) Teitl

Lot 14 - Von willebrands factor - Recombinant

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 15

II.2.1) Teitl

Lot 15 - Fibrinogen Concentrate

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 16

II.2.1) Teitl

Lot 16 - Prothrombin Complex dried

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 17

II.2.1) Teitl

Lot 17 - Protein C Concentrate

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 18

II.2.1) Teitl

Lot 18 - Fresh Frozen Plasma

II.2.2) Cod(au) CPV ychwanegol

33141530

II.2.3) Man cyflawni

Cod NUTS:

UK


Prif safle neu fan cyflawni:

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

II.2.4) Disgrifiad o’r caffaeliad

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Dechrau: 01/07/2022

Diwedd: 30/06/2024

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Section III: Gwybodaeth gyfreithiol, economaidd, ariannol a thechnegol

III.1) Amodau ar gyfer cymryd rhan

III.1.2) Statws economaidd ac ariannol

Meini prawf dethol fel y’u nodir yn y dogfennau caffael


III.1.3) Gallu technegol a phroffesiynol

Meini prawf dethol fel y’u nodir yn y dogfennau caffael


III.2) Amodau sy’n gysylltiedig â’r contract

Section IV: Gweithdrefn

IV.1) Disgrifiad

IV.1.1) Y math o weithdrefn

Gweithdrefn agored

IV.1.3) Gwybodaeth am gytundeb fframwaith neu system brynu ddynamig

The procurement involves the establishment of a framework agreement with several operators.

IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)

The procurement is covered by the Government Procurement Agreement: Ydy

IV.2) Gwybodaeth weinyddol

IV.2.2) Terfyn amser i dendrau neu geisiadau i gymryd rhan ddod i law

Dyddiad: 14/02/2022

Amser lleol: 13:00

IV.2.4) Ym mha iaith/ieithoedd y gellir cyflwyno tendrau neu geisiadau i gymryd rhan

EN

IV.2.6) Yr isafswm cyfnod gofynnol i’r sawl sy’n tendro gynnal y tendr

Rhaid i’r tendr fod yn ddilys tan: 15/05/2022

IV.2.7) Amodau ar gyfer agor tendrau

Dyddiad: 14/02/2022

Amser lleol: 13:00

Place:

Runcorn

Gwybodaeth am bersonau awdurdodedig a'r weithdrefn agor:

Commercial Medicines Unit Employee

Section VI: Gwybodaeth ategol

VI.1) Gwybodaeth am ailddigwydd

Caffaeliad cylchol yw hwn: Na

VI.2) Gwybodaeth am lifau gwaith electronig

Defnyddir archebion electronig

Derbynnir anfonebau electronig

Defnyddir taliadau electronig

VI.3) Gwybodaeth ychwanegol

RESPONDING TO THIS NOTICE:<br/>Any supplier may be disqualified who does not respond to the following in the requisite manner:<br/>1) Submission of expression of interest and procurement specific information<br/>This procurement exercise will be conducted on the eTendering portal at<br/>https://healthfamily.force.com/s/Welcome<br/>Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific<br/>information (if requested) through the eTendering portal as follows:<br/>1.1) If not already registered, Candidatesshould register on the eTendering portal at<br/>https://health-family.force.com/s/Welcome and<br/>click the link to register:<br/>- agree to the user agreement<br/>- populate company details<br/>1.2) Once registered, candidates must register interest as follows:<br/>- log to the portal<br/>- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select <br/>review opportunity details and click "Register Interest"<br/>- as you select the opportunity, you can review documents, send clarification messages,submit the response or decline to respond (if<br/>you decide not to participate in the opportunity)<br/>1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis help desk at supporthealth@<br/>atamis.co.uk or by calling 0800 9956035 for technical assistance when<br/>completing responses.<br/>2) General supplier information.<br/>To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:<br/>2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the<br/>following web page<br/>https://supplierregistration.cabinetoffice.gov.uk and select "Register" at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S®Number, click on the link at the right of the page to obtain a number from D&B.<br/>Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.<br/>2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.<br/>D&B data will be supplied automatically by D&B.<br/>2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the message function on the website.<br/>OTHER CONTRACTING AUTHORITIES<br/>The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together<br/>as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or<br/>goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare<br/>or health related services.

VI.4) Gweithdrefnau adolygu

VI.4.1) Corff adolygu

The High Court

Strand

London

WC2A 2LL

UK

E-bost: generaloffice@administrativecourtoffice.justice.gov.uk

Cyfeiriad(au) rhyngrwyd

URL: https://www.gov.uk/courts-tribunals

VI.5) Dyddiad anfon yr hysbysiad hwn

07/01/2022

Codio

Categorïau nwyddau

ID Teitl Prif gategori
33141530 Ceulyddion gwaed Defnyddiau traul anghemegol meddygol a defnyddiau traul haematolegol untro

Lleoliadau Dosbarthu

ID Disgrifiad
100 DU - I gyd

Cyfyngiadau Rhanbarthol ar y Rhybuddion

Mae’r prynwr wedi cyfyngu’r rhybuddion ar gyfer yr hysbysiad hwn i gyflenwyr yn y rhanbarthau canlynol.

ID Disgrifiad
Nid oes cyfyngiadau ar y rhybuddion ar gyfer yr hysbysiad hwn.

Ynglŷn â'r prynwr

Prif gyswllt:
philip.grieve@nhs.net
Cyswllt gweinyddol:
N/a
Cyswllt technegol:
N/a
Cyswllt arall:
N/a

Gwybodaeth bellach

Dyddiad Manylion
Nid oes unrhyw wybodaeth bellach wedi'i lanlwytho.

0800 222 9004

Mae'r llinellau ar agor rhwng 8:30am a 5pm o ddydd Llun i ddydd Gwener.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.